XTLB

XTL Biopharmaceuticals Ltd.

0.85 USD
+0.02 (+2.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

XTL Biopharmaceuticals Ltd. stock is down -3.41% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.63% of the previous 18 February’s closed higher than January.

About XTL Biopharmaceuticals Ltd.

The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.